Vaxart Inc (VXRT)
0.8229
+0.01
(+1.11%)
USD |
NASDAQ |
May 31, 16:00
0.8263
0.00 (0.00%)
After-Hours: 20:00
Vaxart SG&A Expense (Quarterly): 7.238M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.238M |
December 31, 2023 | 5.44M |
September 30, 2023 | 4.921M |
June 30, 2023 | 5.598M |
March 31, 2023 | 6.625M |
December 31, 2022 | 6.447M |
September 30, 2022 | 6.96M |
June 30, 2022 | 9.321M |
March 31, 2022 | 6.658M |
December 31, 2021 | 5.754M |
September 30, 2021 | 5.042M |
June 30, 2021 | 5.15M |
March 31, 2021 | 5.944M |
December 31, 2020 | 5.126M |
September 30, 2020 | 4.19M |
June 30, 2020 | 3.896M |
March 31, 2020 | 1.99M |
December 31, 2019 | 1.331M |
September 30, 2019 | 1.455M |
June 30, 2019 | 1.375M |
March 31, 2019 | 2.026M |
December 31, 2018 | 1.226M |
September 30, 2018 | 1.674M |
June 30, 2018 | 1.771M |
March 31, 2018 | 2.01M |
Date | Value |
---|---|
December 31, 2017 | 2.60M |
September 30, 2017 | 1.70M |
June 30, 2017 | 1.50M |
March 31, 2017 | 1.30M |
December 31, 2016 | 1.50M |
September 30, 2016 | 1.40M |
June 30, 2016 | 1.00M |
March 31, 2016 | 1.50M |
December 31, 2015 | 1.50M |
September 30, 2015 | 1.60M |
June 30, 2015 | 0.60M |
March 31, 2015 | 2.40M |
December 31, 2014 | 2.00M |
September 30, 2014 | 1.70M |
June 30, 2014 | 1.20M |
March 31, 2014 | 1.80M |
December 31, 2013 | 2.10M |
September 30, 2013 | 1.70M |
June 30, 2013 | 7.20M |
March 31, 2013 | 2.10M |
December 31, 2012 | 2.80M |
September 30, 2012 | 1.605M |
June 30, 2012 | 2.176M |
March 31, 2012 | 1.277M |
December 31, 2011 | 1.313M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.331M
Minimum
Dec 2019
9.321M
Maximum
Jun 2022
5.023M
Average
5.295M
Median
SG&A Expense (Quarterly) Benchmarks
Novavax Inc | 86.80M |
Allogene Therapeutics Inc | 17.27M |
Inovio Pharmaceuticals Inc | 10.57M |
Stereotaxis Inc | 6.469M |
Arcturus Therapeutics Holdings Inc | 14.85M |